Iomai, GlaxoSmithKline, Novartis, U.S. Department of Health and Human Services infectious news

HHS awarded $132.5 million to three companies to develop adjuvant-based vaccines and adjuvants for H5N1 avian influenza. GSK will

Read the full 194 word article

How to gain access

Continue reading with a
two-week free trial.